SEC Form 4 · accession 0001649904-26-000013
RHYTHM PHARMACEUTICALS, INC. · RYTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alastair Garfield
Officer — Chief Scientific Officer
Period of report
Aug 13, 2026
Accepted (ET)
Aug 17, 2026 · 5:57 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649904
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 13, 2026 | S | 2,007 | $116.1093 | D | 8,051 | D | |
| Common StockF3 | Aug 13, 2026 | S | 1,556 | $117.0759 | D | 6,495 | D | |
| Common StockF4 | Aug 13, 2026 | S | 3,400 | $118.2843 | D | 3,095 | D | |
| Common StockF5 | Aug 13, 2026 | S | 800 | $119.1688 | D | 2,295 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.
- F2The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.67 to $116.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.72 to $117.66 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $117.73 to $118.71 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $118.73 to $119.52 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.